What is the first‑line FDA‑approved medication and dosing schedule for treating bulimia nervosa (binge‑eating with purging)?

First-Line Medication for Bulimia Nervosa (Binge-Eating with Purging)

Fluoxetine 60 mg once daily (administered in the morning) is the only FDA-approved medication and the recommended first-line pharmacologic treatment for bulimia nervosa, demonstrating statistically significant superiority over placebo in reducing binge-eating and purging frequency. 1, 2, 3

Dosing and Administration

• Start fluoxetine at 60 mg daily taken in the morning—this is the evidence-based dose for bulimia nervosa, not the standard 20 mg antidepressant dose 1, 2, 3
• The American Psychiatric Association explicitly advises against using standard antidepressant doses (20 mg) for bulimia nervosa, as the therapeutic effect for eating disorder symptoms requires the higher 60 mg dose 1
• This dose was established through 8- to 16-week trials in adult outpatients with moderate to severe bulimia nervosa (defined as ≥3 bulimic episodes per week for 6 months) 3

Integration with Psychotherapy

• Fluoxetine should be initiated alongside eating disorder-focused cognitive-behavioral therapy (CBT), which remains the cornerstone psychological treatment 1, 2
• Alternatively, fluoxetine may be added if there is minimal or no response to psychotherapy alone by 6 weeks of treatment 1
• Treatment requires coordination among medical, psychiatric, psychological, and nutritional expertise 2

Pre-Treatment Assessment Requirements

Before initiating fluoxetine, the American Psychiatric Association mandates:

• Comprehensive evaluation including weighing the patient and quantifying eating and weight control behaviors 2
• Physical examination with vital signs, height, weight, BMI, and assessment for signs of purging behaviors 2
• Laboratory assessment including complete blood count, comprehensive metabolic panel, electrolytes, liver enzymes, and renal function tests 2
• Electrocardiogram for patients with severe purging behavior, as electrolyte disturbances can prolong QTc interval 2
• Identification of co-occurring psychiatric disorders, which are common in bulimia nervosa 2

Monitoring and Duration

• Fluoxetine has demonstrated efficacy in maintaining response for up to 52 weeks in patients who responded during an 8-week acute treatment phase 3
• The physician should periodically reevaluate the long-term usefulness of fluoxetine for the individual patient during extended treatment 3

Alternative Options for Fluoxetine Intolerance

If fluoxetine is not tolerated:

• Sertraline 100 mg daily is the recommended alternative SSRI, with moderate-quality evidence showing reduction in binge-eating and purging episodes over 12 weeks 1
• Citalopram may be particularly useful in patients with prominent comorbid depressive symptoms 1
• Patients should continue CBT focused on eating disorders while transitioning to alternative SSRI treatment 1

Critical Pitfall to Avoid

Do not prescribe fluoxetine 20 mg daily for bulimia nervosa—the American Psychiatric Association specifically warns that standard antidepressant dosing is inadequate for eating disorder symptoms, and 60 mg daily is required for therapeutic effect 1

Safety Profile

• Fluoxetine for bulimia nervosa is relatively safe and well-tolerated based on randomized controlled trials, open-label trials, and case reports 4
• Common side effects are consistent with SSRI class effects (nausea, headache, insomnia, sexual dysfunction), but treatment-emergent adverse events infrequently lead to discontinuation 4, 5